Genetix Unveils Its Rapid Turnaround Into a Profitable, High-Growth Commercial Leader in Genetic Medicine for Rare Disease

SOMERVILLE, Mass.–(BUSINESS WIRE)–Genetix Biotherapeutics Inc., the commercial leader in genetic medicine for rare disease with a focus on hematology, today unveiled its rapid turnaround into a profitable commercial enterprise and announced strong 2026 commercial performance, a multibillion-dollar growth trajectory, and strategic priorities. The company shared the update in a presentation by CEO David Meek at the Jefferies Global Healthcare Conference in London, UK. Genetix has established a

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.